Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

← catalyst calendar

NCT04437511 · results posted

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,736actual
Sites
274
Countries
Australia, Canada, Czechia +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-06-19actualWhen the study began enrolling
Primary completion2023-04-14actualThe date the last participant is measured for the primary outcome — the readout window
Study completionNov 2028estimatedThe whole study's end, after follow-up
First posted2020-06-18actualWhen this record first appeared on the registry
Results posted2024-05-20actualWhen the sponsor posted results to the registry
Record updated2025-08-29actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Alzheimer Disease

Interventions

  • Drug: Donanemab — also filed as LY3002813
  • Drug: Placebo

Primary outcomes

what the primary-completion date above is the date OF
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Overall Population)
measured Baseline, Week 76
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) (Intermediate (Low-medium) Tau Population)
measured Baseline, Week 76

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2022-11-10 · 1.3 MB · Prot_000.pdf
Statistical Analysis Planposted 2023-04-20 · 740 KB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed